Derniers articles

Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer

AbstractContext and aims: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast...

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : Clin Breast Cancer.

Interaction analysis of subgroup effects in randomized trials: the essential methodological points

AbstractSubgroup analysis aims to identify subgroups (usually defined by baseline/demographic characteristics), who...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Sci Rep.

Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study

AbstractBackground: Stage II colon cancer (CC) exhibits considerable prognostic heterogeneous. Our objective was to...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Clin Colorectal Cancer.

Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases

AbstractBackground: Small bowel adenocarcinoma is a rare disease. The genomic profiling tumours according to...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Br J Cancer.

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability

AbstractBackground: One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer.

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

AbstractBackground: The modified docetaxel, cisplatin, and fluorouracil (mDCF) regimen has shown efficacy and...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol.

Does Kono-S Anastomosis Reduce Recurrence in Crohn's Disease Compared with Conventional Ileocolonic Anastomosis? A Nationwide Propensity Score-matched Study from GETAID Chirurgie Group [KoCoRICCO Study]

AbstractBackground and aims: Postoperative recurrence is a major concern in Crohn's disease. The Kono-S anastomosis...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : J Crohns Colitis.

Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort

AbstractBackground & aims: Accumulating data has shown the rising incidence and poor prognosis of early-onset...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Liver Int.

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer

AbstractBackground: It is intuitively thought that early relapse is associated with poor survival after recurrence...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer.

KONO-S Anastomosis Is Not Superior to Conventional Anastomosis for the Reduction of Postoperative Endoscopic Recurrence in Crohn's Disease

AbstractBackground: Surgical resection rates remain high in Crohn's disease (CD). Reducing postoperative recurrence...

Posté par : Dr. Dewi VERNEREY, Mr. Antoine FALCOZ
Nom de la revue : Inflamm Bowel Dis.

Transfused Red Blood Cell Characteristics and Kidney Transplant Outcomes Among Patients Receiving Early Posttransplant Transfusion

AbstractImportance: Red blood cell transfusion (RBCT) is frequently required in the early post-kidney transplant...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : JAMA Netw Open

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study

AbstractBackground: Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : JNCI Cancer Spectr.

Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

AbstractAims: The EXTREME regimen is the standard for recurrent and/or metastatic head and neck squamous cell...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Clin Oncol (R Coll Radiol)

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)

AbstractBackground: Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study

AbstractTriplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Exp Hematol Oncol

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

AbstractPurpose: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol .

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

AbstractPurpose: Baseline circulating tumour DNA (ctDNA) is a potential prognostic marker in metastatic colorectal...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi

AbstractOverview of biliary tract cancer management practices in France: results of the ACABi national survey...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Bull Cancer

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

AbstractBackground: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive...

Posté par : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Front Cardiovasc Med

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

AbstractPurpose: Universal cancer peptide-based vaccine (UCPVax) is a therapeutic vaccine composed of two highly...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : J Clin Oncol